NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models.

ABSTRACT: Beginning at early stages, human Alzheimer's disease (AD) brains manifest hyperexcitability, contributing to subsequent extensive synapse loss, which has been linked to cognitive dysfunction. No current therapy for AD is disease-modifying. Part of the problem with AD drug discovery is that transgenic mouse models have been poor predictors of potential human treatment. While it is undoubtedly important to test drugs in these animal models, additional evidence for drug efficacy in a human context might improve our chances of success. Accordingly, in order to test drugs in a human context, we have developed a platform of physiological assays using patch-clamp electrophysiology, calcium imaging, and multielectrode array (MEA) experiments on human (h)iPSC-derived 2D cortical neuronal cultures a

SUBMITTER: Ghatak S 

PROVIDER: S-EPMC7704704 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature